Post by Johnson & Johnson Innovative Medicine

Our blood cancer portfolio is defined by breakthrough science and proven progress. With new late-breaking data, we’re expanding treatment possibilities and addressing unmet needs globally.    Our data at this year’s #ASH25 is poised to be some of the best yet. From #MultipleMyeloma to #AcuteMyeloidLeukemia, our innovation continues to redefine what’s possible for the future of blood cancer care.    Our ambition is to get #InFrontofCancer, and we are driving toward that goal every day on behalf of patients, caregivers and health care providers: https://bit.ly/3KcA1FN    #JNJOncology